The 8p11 myeloproliferative syndrome: Genotypic and phenotypic classification and targeted therapy.

Li, Taotao; Zhang, Gaoling; Zhang, Xiaoling; Lin, Hai; Liu, Qiuju

Li, Taotao; Zhang, Gaoling; Zhang, Xiaoling; Lin, Hai; Liu, Qiuju.

Afiliación

Li T; Department of Hematology, The First Hospital of Jilin University, Changchun, China.
Zhang G; Department of Hematology, The First Hospital of Jilin University, Changchun, China.
Zhang X; Key Laboratory of Organ Regeneration and Transplantation of Ministry of Education, First Hospital, Jilin University, Changchun, China.
Lin H; National-Local Joint Engineering Laboratory of Animal Models for Human Disease, First Hospital, Jilin University, Changchun, China.
Liu Q; Department of Hematology, The First Hospital of Jilin University, Changchun, China.

Front Oncol ; 12: 1015792, 2022.

Article en En | MEDLINE | ID: mdl-36408177

Palabras clave

EMS; FGFR1 rearrangement; infigratinib; pemigatinib; targeted therapy; tyrosine kinase inhibitors

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Oncol Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google